(Q40703422)

22 September 2017

title

Switching previous therapies for Alzheimer's disease to galantamine (English)

1 reference

22 September 2017

0 references

1

1 reference

22 September 2017

publication date

1 January 2001

1 reference

22 September 2017

published in

Clinical Therapeutics

1 reference

22 September 2017

volume

23 Suppl A

1 reference

22 September 2017

page(s)

A3-7

1 reference

Treatment of Alzheimer's disease

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980162-4

7 January 2021

10.1016/S0149-2918(01)80162-4

Identifiers

DOI

1 reference

22 September 2017

1 reference